Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation recently completed a Phase 3 clinical ...

AstraZeneca (($AZN)) announced an update on their ongoing clinical study. Study Overview: The DESTINY-Endometrial01 study aims to evaluate the ...

The KEYNOTE-905 study is ongoing and will evaluate other endpoints including EFS, OS, and pCR rate for neoadjuvant and adjuvant pembrolizumab vs surgery alone.

A research team co-led by UCLA investigators has found that pembrolizumab, an immunotherapy drug that helps the immune system ...

New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...

This article highlights recent research on breast cancer, lung cancer, melanoma, head and neck cancer, and hematologic malignancies.

Topline results were announced from a phase 3 trial evaluating Cylembio (imsapepimut and etimupepimut, adjuvanted) in combination with pembrolizumab as a first-line treatment for advanced melanoma.

UCLA’s cancer research has been deeply impactful, with millions of people receiving drugs and therapies developed in Bruin ...